News

Under a named patient program (NPP), investigational drugs can be administered to patients who are suffering from serious illnesses until the drug is approved by the European Medicines

Under the agreement, Alfacell has granted Megapharm exclusive rights in the defined territory for the marketing, sales and distribution of Onconase. Alfacell will receive 50% of all sales

ThermaCare will join the company’s pain franchise that includes Advil – one of the world’s leading oral pain relievers – and will enhance Wyeth’s global position in pain

The expanded partnership will give researchers at Mitsubishi Tanabe preferred access to Metabolon’s global biochemical profiling services. Completing research studies using Metabolon’s services, Mitsubishi Tanabe has gained insight

Genentech’s Activase, a recombinant tissue plasminogen activator is approved for the management of acute ischemic stroke in adults. Through this agreement, the companies will collaborate and Genentech will

Remedi SeniorCare, formerly Woodhaven Health Services, will now serve more than 20,000 residents in Maryland, Delaware, Washington DC, Virginia, Ohio, Kentucky, Indiana and Michigan. All Remedi SeniorCare customers

Technology4Medicine will sell MedX Health’s newest laser product, Oralase immediately upon clearances from the FDA to dental offices. Oralase is said to be a low level laser therapy

The investment and collaboration will help support continued development of Abeome’s lead ovarian cancer project. Abeome’s proprietary technology improves the development of monoclonal antibodies and Abeome is deploying

This Phase II double-blind study (study RX-3341-201) will evaluate the safety and efficacy of RX-3341 at two different doses administered intravenously to hospitalized complicated skin and skin structure